iifl-logo

Gland Pharma Ltd Historical Data

Add as a Preferred Source on Google
₹3,331.9
(1.18%)
Nov 20, 2026|03:56:15 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

Gland Pharma Ltd Historical Data

21/10/2026calendar-icon
21/11/2026calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

21-Oct-2026

3,005.1

3,028.32,839.62,9351,48,5523,50,38,60,0817,30,701

22-Oct-2026

2,906.1

2,953.92,8292,850.444,61097,61,75,3421,87,517

23-Oct-2026

2,848.9

2,9242,769.82,826.866,6121,19,06,62,764.72,35,278

26-Oct-2026

2,815

2,867.82,788.42,843.943,7801,36,13,10,186.23,30,143

27-Oct-2026

2,858.9

3,0002,858.92,960.365,1991,17,87,01,943.72,14,076

28-Oct-2026

2,950

3,061.52,9243,04937,79985,17,49,954.41,29,014

29-Oct-2026

3,060

3,111.23,0113,074.547,7321,18,74,67,437.52,64,576

30-Oct-2026

3,070

3,114.23,0513,095.939,96592,89,17,776.41,82,087

02-Nov-2026

3,095.9

3,114.93,0353,066.631,09967,25,58,503.81,21,815

03-Nov-2026

3,120.9

3,168.33,0353,158.980,0371,75,55,73,426.43,02,172

04-Nov-2026

3,161.6

3,1743,124.53,15942,3101,31,03,61,9323,31,236

05-Nov-2026

3,170

3,208.63,101.33,145.248,5051,48,76,13,311.63,42,809

06-Nov-2026

3,150

3,183.43,133.23,169.338,9541,11,44,19,932.32,04,609

08-Nov-2026

3,185

3,1993,082.23,132.810,92531,53,12,989.942,301

09-Nov-2026

3,147

3,3743,140.83,302.42,16,2188,07,63,54,412.35,60,058

11-Nov-2026

3,344.6

3,370.53,233.13,263.958,0031,80,97,85,335.52,91,382

12-Nov-2026

3,268.5

3,3473,268.53,308.741,83474,25,48,249.41,17,717

13-Nov-2026

3,339.7

3,3553,307.23,334.130,11769,08,46,022.51,02,074

16-Nov-2026

3,350.8

3,4293,3413,385.962,1641,42,00,80,032.41,89,715

17-Nov-2026

3,380

3,395.93,222.43,248.438,87788,31,23,386.81,34,157

18-Nov-2026

3,260

3,2783,208.73,230.541,94079,66,61,136.11,30,036

19-Nov-2026

3,230.5

3,2983,222.63,292.928,14339,14,09,486.264,975

Gland Pharma: Related NEWS

Gland Pharma Stock Gains 7% as Q3 Revenue Climbs 22.5% to ₹1,695.3 Crore

The European business reported a 54 percent year on year surge in topline during the quarter.

29 Jan 2026|12:20 PM
Read More
Top Stocks for Today - 8th January 2026

Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.

8 Jan 2026|07:31 AM
Read More
Top Stocks for Today - 4th November 2025

Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.

4 Nov 2025|08:01 AM
Read More
Top Stocks for Today - 14th July 2025

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.

14 Jul 2025|06:30 AM
Read More
Gland Pharma Gets USFDA Clearance for Visakhapatnam Facility

The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.

25 Jun 2025|12:07 PM
Read More
Top Stocks for Today - 5th June 2025

Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.

5 Jun 2025|07:53 AM
Read More
Gland Pharma gets USFDA approval for blood pressure drug

Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.

4 Jun 2025|03:34 PM
Read More
Gland Pharma Q4 Net Profit Declines 3.1% to ₹186.5 Crore; Revenue Down 7.3% YoY

Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.

22 May 2025|08:49 AM
Read More
Gland Pharma Gets USFDA Nod for Glaucoma Drug

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US

30 Apr 2025|03:40 PM
Read More
USFDA Issues Three Observations to Gland Pharma's Visakhapatnam Facility

The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.

26 Feb 2025|12:22 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.